Loading stock data…
CervoMed Inc. (CRVO)
$2.53-0.03 (-1.17%)
Market ClosedLast close Sep 8
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CervoMed Inc. in the Healthcare sector is trading at $2.53 with a market capitalization of $38M. Wall Street consensus targets $15.40 (5 analysts), implying a +508.7% move over the next 12 months. The stock is currently near its 52-week low of $2.13, remaining 45.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +508.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.68M↑ | -$8.11M↑ | -$8.33M↓ | -$8.04M↓ | -$6.62M |
| Net Income | -$6.57M↑ | -$7.96M↑ | -$8.09M↓ | -$7.73M↓ | -$6.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosse...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-4.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-132.18%
Volume
Today's trading volume
392,643
Recent News
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally
The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.
Top Midday Gainers
CervoMed (CRVO) received a notice of allowance from the US Patent and Trademark Office for a patent
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)
CervoMed Inc. (NASDAQ:CRVO) shares climbed 20% on Thursday after the company announced it had received a notice of allowance from the U.